{"schema_version":"1.0","type":"article","title":"本週醫藥交易：吉利德先付13億美元搶口服IL-23","url":"https://drugnews.com.tw/articles/2026-10-26-weekly-deals-gilead-pepstar-hansoh-roche.html","markdown_url":"https://drugnews.com.tw/articles/2026-10-26-weekly-deals-gilead-pepstar-hansoh-roche.md","lang":"zh-Hant","date":"2026-10-26","publish_at":"2026-10-26T19:30:00+08:00","updated_at":"2026-10-26","category":"商業分析系列","topic":"BD / 授權","tags":["全球醫藥交易週報","吉利德 Gilead","翰森製藥","禮來 Eli Lilly","IL-23"],"summary":"吉利德 10/23 以 13 億美元現金預付取得中國 PepStar 的口服 IL-23 受體藥；同週翰森 × 羅氏頭條逾 155 億美元、首付 4 億。本週 6 件醫藥大事，用「簽約當下付多少現金」這把尺看。","key_points":["吉利德（Gilead）2026 年 10 月 23 日以 13 億美元現金預付取得中國 PepStar 的口服 IL-23 受體環狀胜肽 HCXT-2001（IBD），里程碑未揭露（BioSpace）。","翰森製藥 2026 年 10 月 19 日與羅氏簽 ADC 組合授權：首付 4 億美元、一週年 1.1 億美元、里程碑逾 150 億美元，首付約占頭條總額 2.6%。","禮來 2026 年 10 月 19 日與香港 METiS 簽 AI 脂質奈米顆粒平台合作，首付低雙位數百萬美元、總額最高 11 億美元，首付不到 2%。"],"facts":[],"sections":["01｜吉利德：13 億美元全付現，買一顆口服 IL-23 藥","02｜翰森 × 羅氏：155 億美元的頭條，首付 2.6%","03｜禮來 × METiS：11 億美元買「把藥送到對的地方」","04｜德國默克：13 億美元買下 Silence，換掉放血","05｜GSK 的一週：直腸癌免開刀、B 肝有機會停藥","06｜同一週，IL-23 的打針藥也在變方便","參考資料"],"references":[{"title":"Gilead shops in IL-23, inking $1.3B upfront I&I deal with China's PepStar","source":"BioSpace","date":"2026-10-23","url":"https://www.biospace.com/business/gilead-shops-in-il-23-inking-1-3b-upfront-i-i-deal-with-chinas-pepstar"},{"title":"翰森製藥與羅氏達成戰略合作及授權協議","source":"翰森製藥","date":"2026-10-19","url":"https://www.hansoh.cn/news/news-detail-514090.htm"},{"title":"Lilly partners with Hong Kong's Metis in $1.1B deal to bolster AI nanoparticle discovery","source":"Fierce Biotech","date":"2026-10-19","url":"https://www.fiercebiotech.com/biotech/lilly-partners-hong-kongs-metis-11b-deal-bolster-ai-nanoparticle-discovery"},{"title":"Merck KGaA, Darmstadt, Germany to Acquire Silence Therapeutics","source":"Business Wire","date":"2026-10-19","url":"https://www.businesswire.com/news/home/20261019777870/en/Merck-KGaA-Darmstadt-Germany-to-Acquire-Silence-Therapeutics-Strengthening-Rare-Disease-Pipeline-with-Innovative-siRNA-Asset"},{"title":"FDA Approves Immunotherapy That May Allow Certain Patients with Rectal Cancer to Avoid Chemotherapy, Radiation and Surgery","source":"FDA","date":"2026-10-19","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-immunotherapy-may-allow-certain-patients-rectal-cancer-avoid-chemotherapy-radiation-and"},{"title":"FDA Approves First-of-Its-Kind Chronic Hepatitis B Treatment","source":"FDA","date":"2026-10-20","url":"https://www.fda.gov/news-events/press-announcements/fda-approves-first-its-kind-chronic-hepatitis-b-treatment"},{"title":"U.S. FDA Approves Subcutaneous Induction Regimen for AbbVie's SKYRIZI for Adults With Moderately to Severely Active Crohn's Disease","source":"AbbVie（PR Newswire","date":"2026-10-23","url":""}],"images":[{"alt":"這週誰真的先掏錢？簽約當下付出的現金","url":"https://drugnews.com.tw/assets/articles/weekly-deals-gilead-pepstar-hansoh-roche/figure-01.png"}],"cover_image":"https://drugnews.com.tw/assets/articles/weekly-deals-gilead-pepstar-hansoh-roche/cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-10-26）。本週醫藥交易：吉利德先付13億美元搶口服IL-23。https://drugnews.com.tw/articles/2026-10-26-weekly-deals-gilead-pepstar-hansoh-roche.html","disclaimer":"本文僅供產業研究與知識分享，不構成投資、醫療、募資或個股建議。","translations":{},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}